The Relationship Between Arsenic Methylation Capability and Blood Metals in Children With Developmental Delays

The Relationship Between Genetic Polymorphism of Arsenic Methylation Enzymes, Arsenic Methylation Capability and Blood Metals, and Developmental Delays in Preschool Children

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02523989

Enrollment

137

Registered

2015-08-14

Start date

2010-03-31

Completion date

2011-07-31

Last updated

2015-08-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Developmental Delays

Keywords

arsenic, heavy metal

Brief summary

The purpose of this study is to explore the relationship between arsenic methylation and blood metals in children with developmental delays and its correlation with health related quality of life.

Detailed description

The investigators recruited children with developmental delays and children with normal development from Shin-Kong Ho-Su Memorial Hospital as controls. Information obtained from the interview included socioeconomic and basic demographic characteristics as well as children function, health condition, and quality of life. On the other hand, blood and urine samples of the participants were collected for the analysis of arsenic methylation related enzymes using polymerase chain reaction and restriction fragment length polymorphism. 2 ml blood were digested for the determination of mercury, lead and arsenic. The relationship between arsenic methylation and blood metals in children with developmental delays and its correlation with health related quality of were analyzed.

Interventions

OTHERstudy group

Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.

Study design

Observational model

CASE_CONTROL

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

2 Years to 12 Years

Healthy volunteers

Yes

Inclusion criteria

Study group: Inclusion Criteria: * children with developmental delays obtained written informed consent from parents

Exclusion criteria

* parents refused for participation of their children to the intervention failed to obtain the written informed consent from parents Control group: Inclusion Criteria: * children with normal development obtained written informed consent from parents

Design outcomes

Primary

Measure	Time frame	Description
heavy metal assessment	3 months	laboratory analysis

Secondary

Measure	Time frame	Description
quality of life	2 weeks	questionnaires analysis

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026